ivosidenib,magrolimab,venetoclax,azacitidine
abbvie,roche,servier,gilead sciences
['azacitidine,(-oral azaci),(-azacitidine oral)', 'ivosidenib', 'triplet', 'venetoclax', 'leukemia', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops)', 'magrolimab']
 addition of venetoclax +/- azacitidine to ivosidenib = responses in idh1 mutated aml promising activity of azacitidine + magrolimab with 50% mrd negativity looking forward for exciting triplets #asco22 #leukemia #leusm 
Leukemia Fellow                                                                 
    MD Anderson Cancer Center, Houston